Xatral XL

Phase 1Small molecule

IInternational Bio service

Xatral XL is one of 3 small molecule programs targeting Prolonged. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProlongedNot yet recruiting

ProlongedPhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Prolonged

#DrugCompanyPhaseTrials

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 2

Xatral XL

IInternational Bio service

Phase 1

1 3

Alfuzosin Hydrochloride

UUniversity of Minnesota

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prolonged1 trial

Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions

Not yet recruiting·PPharma Nueva·Phase 1·NCT06316336·44 enrolled

Fed1 trial

The Bioequivalence Study of Alfuzosin 10 mg Prolong-released Tablets Under Fed Conditions

Unknown status·IInternational Bio service·Phase 1·NCT06228339·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Xatral XL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xatral XL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xatral XL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — International Bio service company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IInternational Bio service

Xatral XL

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prolonged1 trial

Fed1 trial

References

Drug Info

Quick Facts

Related News